Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1987 1
1989 1
1999 1
2000 1
2003 1
2005 1
2008 3
2009 1
2010 1
2011 3
2012 3
2013 3
2014 3
2015 2
2016 3
2017 4
2018 9
2019 6
2020 10
2021 8
2022 10
2023 5

Text availability

Article attribute

Article type

Publication date

Search Results

74 results

Results by year

Filters applied: . Clear all
Page 1
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
Poeschel V, Held G, Ziepert M, Witzens-Harig M, Holte H, Thurner L, Borchmann P, Viardot A, Soekler M, Keller U, Schmidt C, Truemper L, Mahlberg R, Marks R, Hoeffkes HG, Metzner B, Dierlamm J, Frickhofen N, Haenel M, Neubauer A, Kneba M, Merli F, Tucci A, de Nully Brown P, Federico M, Lengfelder E, di Rocco A, Trappe R, Rosenwald A, Berdel C, Maisenhoelder M, Shpilberg O, Amam J, Christofyllakis K, Hartmann F, Murawski N, Stilgenbauer S, Nickelsen M, Wulf G, Glass B, Schmitz N, Altmann B, Loeffler M, Pfreundschuh M; FLYER Trial Investigators; German Lymphoma Alliance. Poeschel V, et al. Among authors: altmann b. Lancet. 2019 Dec 21;394(10216):2271-2281. doi: 10.1016/S0140-6736(19)33008-9. Lancet. 2019. PMID: 31868632 Clinical Trial.
A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL.
Schmitz N, Truemper L, Bouabdallah K, Ziepert M, Leclerc M, Cartron G, Jaccard A, Reimer P, Wagner E, Wilhelm M, Sanhes L, Lamy T, de Leval L, Rosenwald A, Roussel M, Kroschinsky F, Lindemann W, Dreger P, Viardot A, Milpied N, Gisselbrecht C, Wulf G, Gyan E, Gaulard P, Bay JO, Glass B, Poeschel V, Damaj G, Sibon D, Delmer A, Bilger K, Banos A, Haenel M, Dreyling M, Metzner B, Keller U, Braulke F, Friedrichs B, Nickelsen M, Altmann B, Tournilhac O. Schmitz N, et al. Among authors: altmann b. Blood. 2021 May 13;137(19):2646-2656. doi: 10.1182/blood.2020008825. Blood. 2021. PMID: 33512419 Free PMC article. Clinical Trial.
First-line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma: Results of the B-R-ENDA Trial.
Braulke F, Zettl F, Ziepert M, Viardot A, Kahl C, Prange-Krex G, Korfel A, Dreyling M, Bott A, Wedding U, Reichert D, de Wit M, Hartmann F, Poeschel V, Schmitz N, Witzens-Harig M, Klapper W, Rosenwald A, Wulf G, Altmann B, Trümper L. Braulke F, et al. Among authors: altmann b. Hemasphere. 2022 Dec 1;6(12):e808. doi: 10.1097/HS9.0000000000000808. eCollection 2022 Dec. Hemasphere. 2022. PMID: 36479544 Free PMC article.
Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-cell Lymphoma.
Houot R, Poeschel V, Altmann B, Angel S, Thurner L, Illmer T, Andre M, Dreyling M, Maisonneuve H, Tilly H, Mayer S, Casasnovas O, Le Gouill S, Offner F, Cartron G, Kerkhoff A, Weber T, Hoffmann J, Ziepert M, Klapper W, Itti E, Hellwig D, Natchkebia G, de Leval L, Rosenwald A, Haioun C, Dercle L, Gaulard P, Held G. Houot R, et al. Among authors: altmann b. Hemasphere. 2022 Jan 10;6(2):e672. doi: 10.1097/HS9.0000000000000672. eCollection 2022 Feb. Hemasphere. 2022. PMID: 35028526 Free PMC article.
Doubling rituximab in high-risk patients with aggressive B-cell lymphoma -results of the DENSE-R-MegaCHOEP trial.
Friedrichs B, Nickelsen M, Ziepert M, Altmann B, Haenel M, Viardot A, Schmidt C, Ruebe C, Loeffler M, Pfreundschuh M, Rosenwald A, Glass B, Lenz G, Schmitz N; German high-grade lymphoma Study Group. Friedrichs B, et al. Among authors: altmann b. Br J Haematol. 2019 Mar;184(5):760-768. doi: 10.1111/bjh.15710. Epub 2018 Dec 5. Br J Haematol. 2019. PMID: 30520013 Free article. Clinical Trial.
Age-dependent increase of treatment-related mortality in older patients with aggressive B cell lymphoma: analysis of outcome, treatment feasibility, and toxicity in 1171 elderly patients with aggressive B cell lymphoma-data from phase II and III trials of the DSHNHL (German High-Grade Non-Hodgkin's Lymphoma Study Group).
Zettl F, Ziepert M, Altmann B, Zeynalova S, Held G, Pöschel V, Hohloch K, Wulf GG, Glass B, Schmitz N, Loeffler M, Trümper L. Zettl F, et al. Among authors: altmann b. Ann Hematol. 2021 Apr;100(4):1031-1038. doi: 10.1007/s00277-020-04345-3. Epub 2020 Nov 26. Ann Hematol. 2021. PMID: 33242101 Free PMC article.
[Modern varicose vein surgery].
Bruning G, Altmann B. Bruning G, et al. Among authors: altmann b. Hautarzt. 2011 May;62(5):347-53. doi: 10.1007/s00105-010-2085-6. Hautarzt. 2011. PMID: 21499776 German.
74 results